British Journal of Pharmacology p. 2446 - 2459 (2016)
Update date:2022-08-04
Topics:
Bannister, Mark L
Alvarez-Laviada, Anita
Thomas, N Lowri
Mason, Sammy A
Coleman, Sharon
du Plessis, Christo L
Moran, Abbygail T
Neill-Hall, David
Osman, Hasnah
Bagley, Mark C
MacLeod, Kenneth T
George, Christopher H
Williams, Alan J
Background and Purpose: Flecainide is a use-dependent blocker of cardiac Na+channels. Mechanistic analysis of this block showed that the cationic form of flecainide enters the cytosolic vestibule of the open Na+channel. Flecainide is also effective in the treatment of catecholaminergic polymorphic ventricular tachycardia but, in this condition, its mechanism of action is contentious. We investigated how flecainide derivatives influence Ca2+-release from the sarcoplasmic reticulum through the ryanodine receptor channel (RyR2) and whether this correlates with their effectiveness as blockers of Na+and/or RyR2 channels. Experimental Approach: We compared the ability of fully charged (QX-FL) and neutral (NU-FL) derivatives of flecainide to block individual recombinant human RyR2 channels incorporated into planar phospholipid bilayers, and their effects on the properties of Ca2+sparks in intact adult rat cardiac myocytes. Key Results: Both QX-FL and NU-FL were partial blockers of the non-physiological cytosolic to luminal flux of cations through RyR2 channels but were significantly less effective than flecainide. None of the compounds influenced the physiologically relevant luminal to cytosol cation flux through RyR2 channels. Intracellular flecainide or QX-FL, but not NU-FL, reduced Ca2+spark frequency. Conclusions and Implications: Given its inability to block physiologically relevant cation flux through RyR2 channels, and its lack of efficacy in blocking the cytosolic-to-luminal current, the effect of QX-FL on Ca2+sparks is likely, by analogy with flecainide, to result from Na+channel block. Our data reveal important differences in the interaction of flecainide with sites in the cytosolic vestibules of Na+and RyR2 channels.
View MoreChengdu D-Innovation Pharmaceutical Co., Ltd
Contact:86-28-85105536
Address:1001, B6, No.88 Keyuan South Road, Chengdu Hi-Tech Zone
KAIYUAN CHEMICAL COMPANY LIMITED.
website:http://www.kaiyuanchem.com
Contact:+86-22-59891255/66/77
Address:B-2205, Kuangshi International Building, Yingbin Road, XiangLuo Bay Business District, Binhai New area, Tianjin, China.
HaiNan Periwinkle Pharmaceutical Co.,Ltd.
website:http://www.cchpharm.com/en/index.html
Contact:020-82208978
Address:Gongye road,Wuzhishan city,HaiNan province
WUHAN ENTAI TECHNOLOGY DEVELOPMENT CO.,LTD
Contact:0086-27-82330560
Address:RM1204 Fuhua Building of Wuhan Institute of Technology ,Zhuobao Road ,Wuhan ,China
Guangzhou Probig Fine Chemical Co., Ltd.
Contact:020-86297874
Address:No.2, 1/F, No.20, Hetai Road,Hebian Village, Baiyun District,Guangzhou,China
Doi:10.1002/jhet.5570360214
(1999)Doi:10.1016/S0040-4039(99)00786-8
(1999)Doi:10.1039/j39680001704
(1968)Doi:10.1080/10426500210233
(2002)Doi:10.1021/jo00829a052
(1970)Doi:10.1021/jm00304a013
(1969)